• Natera’s Signatera Genome assay featured in Phase III VOLGA bladder cancer trial results presented at the European Society for Medical Oncology Congress 2026.
• Patients whose circulating tumor DNA cleared before surgery or remained undetectable had better event-free survival than those with persistently detectable levels.
• The findings support the assay’s potential to guide treatment decisions in muscle-invasive bladder cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261027424980) on October 27, 2026, and is solely responsible for the information contained therein.